Journal
LUNG CANCER
Volume 109, Issue -, Pages 58-61Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.lungcan.2017.04.020
Keywords
immune checkpoint inhibitors; immune-related adverse events; nivolumab; Stevens-Johnson syndrome; pruritus; aprepitant
Categories
Ask authors/readers for more resources
Although substantial progress has been made in the treatment of non-small-cell lung cancer (NSCLC) patients with immune checkpoint inhibitors (ICIs), severe immune-related adverse events (irAEs) sometimes occur. Here, we report a case of severe refractory pruritus after Stevens-Johnson syndrome (SJS) in a patient with NSCLC treated with nivolumab. The patient was a 76-year-old Japanese woman with advanced NSCLC treated with nivolumab. After the second dose, she experienced severe rash with mucous involvement. We diagnosed SJS and started 50 mg of oral prednisolone (1 mg/kg). The rash completely resolved after prednisolone was started, but we could not manage the severe pruritus with emollients, antihistamines, and steroids. Finally, we administered aprepitant, an oral neurokinin-1 receptor antagonist, for her refractory pruritus. Her symptoms improved within 5 days. Severe refractory pruritus can arise from ICIs, and aprepitant may be a useful treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available